- Home
- WLTH vs KOD Comparison
WLTH vs KOD Comparison
Compare WLTH & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$27.40
Company Overview
Basic Information| Metric | WLTH | KOD |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WLTH | KOD |
|---|---|---|
| Price | $8.55 | $27.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $17.13 | ★ $28.29 |
| AVG Volume (30 Days) | ★ 1.2M | 602.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.25 | N/A |
| Revenue Next Year | $14.99 | N/A |
| P/E Ratio | $10.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.20 | $1.92 |
| 52 Week High | $14.12 | $31.18 |
Technical Indicators
Market Signals| Indicator | WLTH | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 56.67 |
| Support Level | $7.63 | $21.19 |
| Resistance Level | $9.25 | $30.34 |
| Average True Range (ATR) | 0.66 | 1.96 |
| MACD | 0.15 | 0.48 |
| Stochastic Oscillator | 57.02 | 80.26 |
Price Performance
Historical Comparison WLTH
KOD
About WLTH Wealthfront Corporation Common Stock
Wealthfront Corp is a technology company that built a financial solutions platform for digital natives. Its platform is designed to address the needs of the wealth builders within these generations.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.